Skip to content

Cannabis-based drugs in the treatment of fibromyalgia

Cannabis-based drugs in the treatment of fibromyalgia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00033907
Enrollment
100
Registered
2025-06-12
Start date
2024-02-19
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M79.70

Interventions

Group 1: Prospective, multicenter, non-interventional observational study Inclusion of at least 100 patients with fibromyalgie syndrome Data collection at 4 times The data collection takes place after
query of symptoms before cannabis therapy, symptom change through standard therapy
quality of life improvement since standard therapy start and why cannabis therapy? 2. Questionnaire: After 1-2 months after starting treatment with cannabis therapy, pain intensity is measured, healt

Sponsors

Pharma
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients must be older than 25 years. Diagnosis according to M79.7 must be confirmed; treatment goals must not have been achieved yet. At least two months without cannabis use.

Exclusion criteria

Exclusion criteria: Pregnancy and breastfeeding, history of psychosis/schizophrenia, intolerance/allergies to cannabis prescription drugs and their components

Design outcomes

Primary

MeasureTime frame
Change in pain intensity (NRS scale): Measurement times Start point 0 of therapy without cannabis medication; measurement point 1-2 month with cannabis medication, measurement point 3-4 month with cannabis medication and measurement point 5-6 with cannabis medication Change in health-related quality of life (FIQR scale): Measurement times Start point 0 of therapy without cannabis medication; measurement point 1-2 month with cannabis medication, measurement point 3-4 month with cannabis medication and measurement point 5-6 with cannabis medication

Secondary

MeasureTime frame
Change in drug guideline therapy Compatibility and safety of cannabis prescription drugs

Countries

Germany

Contacts

Public ContactKonrad F. Cimander

Arzt

germany@growbiotech.com00491622305216

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026